Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35428210/
This study is registered at ClinicalTrials.gov (Identifier: NCT04642027 ). Registered on 24 November 2020 - Retrospectively registered. The study protocol was approved by the accredited Medical Ethical Committee (METc) of...
Discussion: Firstly, the high rate of BCR after sEBRT may be due to the presence of oligometastases, for which local sEBRT is inappropriate. With the use of the PSMA PET/CT before sEBRT, patients with oligometastases will be excluded from intensive local treatment to avoid unnecessary toxicity. Secondly, the currently applied radiation dose...
Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial - Radiation Oncology
Source : https://ro-journal.biomedcentral.com/articles/10.1186/s13014-022-02047-w
Background Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7-8 weeks. Recently, moderate hypofractionation with doses per fraction between 2.2 and 4 Gy has been shown to...
Discussion: With moderate hypofractionation being the standard in definitive radiation therapy for localized prostate cancer at many institutions, ultrahypofractionation could be the next step towards reducing treatment time without compromising oncologic outcomes and toxicities. MRI-guided radiotherapy could qualify as an advantageous tool as...
Postoperative radiotherapy in prostate cancer: When and how? - An update review
Source : https://www.sciencedirect.com/science/article/abs/pii/S1278321822000038?via=ihub
Radical prostatectomy (RP) has been found to be curative in most cases of prostate cancer (PCa); however, 20-40% of patients have a biochemical recurrence (BCR) of the disease. Prostatic specific...
Conclusion/Relevance: No guideline exists to select ideal patients for each treatment, but there are tools currently being developed; genetic tests and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) may be able to identify patients with worse outcomes who would benefit from more treatment.
Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer - International Urology and Nephrology
Source : https://link.springer.com/article/10.1007/s11255-022-03156-x
Objectives To report the 10-year oncologic and functional outcomes of whole-gland HIFU as first-line treatment for localized prostate cancer (PCa). Patients and Methods Patients were retrospectively included between January 2005...
Conclusions: HIFU showed low PCa-specific mortality, but biochemical recurrence rates were highly variable among patients. Future studies are needed to improve patient selection.
The role of Ga 68 PSMA PET/CT imaging in Lu 177 PSMA treatment planning in metastatic castration-resistant prostate cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35397091/
It was shown in the present study that Lu 177 PSMA treatment response may be higher in CRPC patients with metastatic bone lesion with high baseline PSMA expression level, and...
Conclusion: It was shown in the present study that Lu177 PSMA treatment response may be higher in CRPC patients with metastatic bone lesion with high baseline PSMA expression level, and better treatment response may be achieved in patients with lymph node metastases than in bone metastases.